While CD4+ T cells have been traditionally regarded as pivotal in NMOSD and multiple sclerosis (MS) pathology, recent studies in human patients have demonstrated that CD8+ T cells instead dominate in MS lesions and display an activated cytotoxic phenotype (31, 32). This evidence concerns the gene CD8A and myeloid sarcoma.